Jubilant Life shares fall on USFDA warning letter

Shares in Jubilant Life Sciences Ltd fell as much as 6.9 per cent on Wednesday after US health regulators issued a warning letter to the company, citing "significant violations" of manufacturing standards at its facility in Canada.

The U.S. Food and Drug Administration may hold drug approvals until Jubilant HollisterStier General Partnership takes necessary corrective steps, Jubilant said in a statement.

Other bigger Indian companies such as Dr. Reddy's Laboratories Ltd, Ranbaxy Laboratories LTd, Sun Pharmaceutical Industries Ltd and Aurobindo Pharma have all received regulatory warning letters on compliance over the last four years.

The company said its on-going manufacturing, distribution and sale of products would not be affected by the warning letter, and it plans to respond to the drug regulator on or before March 15.

Shares in Jubilant Life Sciences, which has a market value of about $548.5 million, fell 4.25 percent to 178 rupees. They earlier touched a low of 173 rupees. The broader market was up 0.67 percent.

EDITORIAL OF THE DAY

  • India cannot afford to ignore the looming Greek crisis

    The crisis in Greece may not have a direct bearing on the Indian economy because the trading or banking exposure of Indian companies to that nation is

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Arun Kumar Jain

A complex challenge for our PSUs

Till the mid-1990s, the central government and its companies were ...

Kuruvilla Pandikattu SJ

The transforming qualities of love

The 2015 Templeton Prize has been awarded to Canadian thinker ...

Dharmendra Khandal

The one in which a blue whale was washed ashore

Quite unexpectedly, a gigantic blue whale was washed ashore at ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture